**Table S3.** Summary of manufacturing and administration results.

| **Patient study number** | **No. NYESOTCRtransgeniccells produced** | **% Viability** | **% NYESOdextramerpositive cells** | **IFN-g withM257A2 (pg/mL/106 cells)** | **No. NYESOTCR transgeniccells infused** | **No. Dose IL-2** | **DC#1 TotalHarvestedCell #****(% of CD86+MHC\_II+ cells)** | **DC#2 TotalHarvestedCell #****(% of CD86+MHC\_II+ cells)** | **DC#3 TotalHarvestedCell #****(% of CD86+MHC\_II+ cells)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ESO-1 | 8.5e8 | 97.15% | 52.3% | 6.2 x 105 | 7.7 x 108 | 28/28 | 2.1 x 107(73.3%) | 2.8 x 107(86.1%) | 2.1 x 107(88.1%) |
| ESO-2 | 3.5e9 | 97.2% | 66.4% | 2.1 x 105 | 1 x 109 | 28/28 | 1.9 x 107(84.2%) | 3.8 x 107(92.9%) | 3.5 x 107(87%) |
| ESO-3 | 3.8e9 | 94.9% | 42.0% | 1.0 x 105 | 1 x 109 | 19/28 | 2.4 x 107(91.9%) | NA | NA |
| ESO-4 | 1.7e9 | 96.2% | 34.1% | 1.3 x 105 | 1 x 109 | 18/28 | 5.2 x 107(71.9%) | 2.3 x 107(89.5%) | 2.2 x 107(88.3%) |
| ESO-5 | 1.6e9 | 96.6% | 61.5% | 2.3 x 105 | 1 x 109 | 14/14 | 1.3 x 108(90.3%) | 2.4 x 107(96.1%) | 1.5 x 107(97.6%) |
| ESO-6 | 2.35e9 | 93.3% | 28.0% | 1.5 x 104 | 1 x 109 | 14/14 | 1.1 x 108(84.9%) | 6 x 107(85.1%) | 4.7 x 107(90.1%) |
| INY-1 | 1.8e9 | 93.4% | 61.8% | 3.97 x 104 | 1 x 109 | 18/28 | 3.9 x 107(94%) | 1.5 x 107(96.1%) | 3.6 x 107(89.3%) |
| INY-2 | 1.4e9 | 96.2% | 71.2% | 2.26 x 105 | 1 x 109 | 21/28 | 11.8 x 107(79.1%) | NA | 2.37 x 107(97.1%) |
| INY-3 | 1.1e9 | 93.7% | 68.0% | 5.3 x 104 | 1 x 109 | 14/14 | 7.1 x 107(99.6%) | 1.7 x 107(99.4%) | 1.4 x 107(97.0%) |
| INY-4 | 1.2e9 | 93.9% | 66.0% | 8.37 x 104 | 1 x 109 | 10/14 | 1.14 x 107(92.6%) | 1.4 x 107(97.2%) | 1.8 x 107(95.2%) |